Alprazolam Tab, USP 0.5mg, (CIV), packaged in: a) 30-count bottle (NDC 68788-7595-3), b) 60-count...
FDA Drug Recall #D-0505-2023 — Class II — March 27, 2023
Recall Summary
| Recall Number | D-0505-2023 |
| Classification | Class II — Moderate risk |
| Date Initiated | March 27, 2023 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Preferred Pharmaceuticals, Inc. |
| Location | Anaheim, CA |
| Product Type | Drugs |
| Quantity | 320 x 30-count; 46 x 60-count; 10 x 90-count bottles |
Product Description
Alprazolam Tab, USP 0.5mg, (CIV), packaged in: a) 30-count bottle (NDC 68788-7595-3), b) 60-count bottle (NDC 68788-7595-6), c) 90-count bottle (NDC 68788-7595-9); Rx Only, Preferred Pharmaceuticals, Inc. Manufactured by: Breckenridge Pharmaceuticals, Inc., Boca Raton, FL.
Reason for Recall
CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.
Distribution Pattern
Nationwide in the USA
Lot / Code Information
Lot # a) D2022P, Exp. Date:4/30/2023; F1022Y, E2022, I2822U, Exp. Date:6/30/2023; L2122W, Exp. Date: 8/31/2024; b) Lot #L0522A, Exp. Date:8/31/2024; B0823J, Exp. Date:11/31/2024; c) Lot# L1522P, Exp. Date: 10/31/2024.
Other Recalls from Preferred Pharmaceuticals, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0239-2026 | Class II | Ondansetron ODT Tablets, USP 4mg, 1x10 unit do... | Nov 17, 2025 |
| D-0391-2025 | Class II | Clindamycin Hydrochloride Capsules, USP, 300mg,... | Apr 18, 2025 |
| D-0647-2024 | Class II | Ibuprofen Tablets, USP 400mg, Generic for Motri... | Aug 8, 2024 |
| D-0505-2024 | Class II | Duloxetine Delayed-Release Cap USP 30mg, 30-cou... | May 10, 2024 |
| D-0894-2023 | Class II | Tizanidine Hydrochloride Tablet 4mg, packaged i... | Jun 26, 2023 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.